Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Dr Dimitris Voliotis appointed Chief Medical Officer

Tuesday, August 20, 2024 1 min read
Key Takeaway: Dr. Dimitris Voliotis has been appointed as the Chief Medical Officer of Radiopharm Theranostics. His extensive experience in the biopharma sector is anticipated to significantly contribute to the company's clinical development efforts. This strategic appointment aligns with Radiopharm's ongoing initiatives in advancing their therapeutic programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Dimitris Voliotis brings extensive experience to the role.
  • The appointment is expected to enhance Radiopharm's clinical strategy.

Full Press Release Details

• Announcements
• August 20, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 19, 2022
• Announcements
• August 26, 2024
• Announcements
• January 31, 2024
• Announcements
• August 23, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

Who is Dr. Dimitris Voliotis?

Dr. Dimitris Voliotis is the newly appointed Chief Medical Officer of Radiopharm Theranostics.

What role will Dr. Voliotis play at Radiopharm?

He will enhance the company's clinical strategy and development efforts.

Why is Dr. Voliotis's appointment significant?

His extensive experience in biopharma is expected to positively impact Radiopharm's initiatives.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Dimitris Voliotis Chief Medical Officer biopharma clinical strategy
Last updated: Aug 20, 2024